- Home
- ABVC vs BOLD Comparison
ABVC vs BOLD Comparison
Compare ABVC & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABVC | BOLD |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 25.7M |
| IPO Year | 2009 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ABVC | BOLD |
|---|---|---|
| Price | $1.08 | $1.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 48.5K | ★ 61.3K |
| Earning Date | 03-03-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.14 | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $509,589.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.74 | $0.96 |
| 52 Week High | $4.02 | $1.78 |
Technical Indicators
Market Signals| Indicator | ABVC | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 35.36 | 49.80 |
| Support Level | N/A | $1.12 |
| Resistance Level | $1.67 | $1.20 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 29.19 | 43.33 |
Price Performance
Historical ComparisonAbout ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.